Newsbenzinga
Cardiff Oncology Announces Presentation Of Phase 2 Trial Data For RAS-Mutated mCRC Treatment Onvansertib At ASCO Annual Meeting On June 2
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…